Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations

被引：2
作者：
Barsotti, Anthony M. [1 ,2 ]
Ryskin, Michael [1 ]
Rollins, Robert A. [1 ]
机构：
[1] Pfizer Worldwide Res & Dev, Oncol Res Unit, Pearl River, NY 10965 USA
[2] Kadmon Pharmaceut, New York, NY 10016 USA
来源：
EPIGENOMICS | 2015年 / 7卷 / 05期
关键词：
epigenetic reprogramming; epigenetic therapy; EZH2; gain-of-function mutations; histone methylation; melanoma; polycomb; B-CELL LYMPHOMAS; LYSINE; 27; MELANOMA; CANCER; HYPERTRIMETHYLATION; INHIBITION; EXPRESSION; LANDSCAPE; PROTEINS; TARGET;
D O I：
10.2217/epi.15.27
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
[No abstract available]
引用
收藏
页码：687 / 690
页数：4
相关论文
共 49 条
  • [21] Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects
    Huang, Rong
    Wu, Yirong
    Zou, Zhengyun
    [J]. EPIGENOMICS, 2022, 14 (22) : 1449 - 1464
  • [22] EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling
    Pang, Bo
    Zheng, Xiang-Rong
    Tian, Jing-xia
    Gao, Tai-hong
    Gu, Guang-yan
    Zhang, Rui
    Fu, Yi-Bing
    Pang, Qi
    Li, Xin-Gang
    Liu, Qian
    [J]. ONCOTARGET, 2016, 7 (29) : 45134 - 45143
  • [23] Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
    Ishi, Yukitomo
    Zhang, Yongzhan
    Zhang, Ali
    Sasaki, Takahiro
    Piunti, Andrea
    Suri, Amreena
    Watanabe, Jun
    Abe, Kouki
    He, Xingyao
    Katagi, Hiroaki
    Bhalla, Pankaj
    Natsumeda, Manabu
    Zou, Lihua
    Shilatifard, Ali
    Hashizume, Rintaro
    [J]. MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 715 - 726
  • [24] Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming
    Tiwari, Neha
    Tiwari, Vijay K.
    Waldmeier, Lorenz
    Balwierz, Piotr J.
    Arnold, Phil
    Pachkov, Mikhail
    Meyer-Schaller, Nathalie
    Schuebeler, Dirk
    van Nimwegen, Erik
    Christofori, Gerhard
    [J]. CANCER CELL, 2013, 23 (06) : 768 - 783
  • [25] Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors
    Guo, Zhirong
    Sun, Yameng
    Liang, Liyun
    Lu, Wenhua
    Luo, Bingling
    Wu, Zhouming
    Huo, Bitao
    Hu, Yumin
    Huang, Peng
    Wu, Qiang
    Wen, Shijun
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (09) : 6573 - 6592
  • [26] HDAC1,2 inhibition impairs EZH2-and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma
    Johnson, Danielle P.
    Spitz, Gabriella S.
    Tharkar, Shweta
    Quayle, Steven N.
    Shearstone, Jeffrey R.
    Jones, Simon
    McDowell, Maria E.
    Wellman, Hannah
    Tyler, Jessica K.
    Cairns, Bradley R.
    Chandrasekharan, Mahesh B.
    Bhaskara, Srividya
    [J]. ONCOTARGET, 2015, 6 (07) : 4863 - 4887
  • [27] Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors
    Wassef, M.
    Michaud, A.
    Margueron, R.
    [J]. CELL CYCLE, 2016, 15 (17) : 2256 - 2262
  • [28] Inhibition of EZH2 primes the cardiac gene activation via removal of epigenetic repression during human direct cardiac reprogramming
    Tang, Yawen
    Zhao, Lianzhong
    Yu, Xufen
    Zhang, Jianyi
    Qian, Li
    Jin, Jian
    Lu, Rui
    Zhou, Yang
    [J]. STEM CELL RESEARCH, 2021, 53
  • [29] Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
    Sun, Ranran
    Shen, Jacson
    Gao, Yan
    Zhou, Yubing
    Yu, Zujiang
    Hornicek, Francis
    Kan, Quancheng
    Duan, Zhenfeng
    [J]. ONCOTARGET, 2016, 7 (25) : 38333 - 38346
  • [30] Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications
    Brown, Robert E.
    Zhang, Songlin
    Wang, Xiaohong I.
    [J]. ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2022, 52 (01) : 27 - 32
12345